MRK MRK メルク

 MRKのチャート


 MRKの企業情報

symbol MRK
会社名 Merck_Co Inc (MRK メルク)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 メルク(Merck_Co. Inc.)はグローバルな医療会社である。同社は処方薬、ワクチン、生物学的療法、動物医薬品を通じて医療ソリューションの提供に従事する。同社は医薬品、動物健康、医療サービス、及びアライアンスという4つの事業区分により構成される。医薬品事業は同社または合弁会社を通じて直接販売されたヒト健康医薬品とワクチン製品を含む。ヒト健康医薬品はヒトの障害の治療のために処方により販売される治療剤・予防剤を含む。同社はヒト健康医薬品医薬品卸売業者・小売業者、病院、政府機関、保健医療機関・薬局給付管理者等の管理医療機関に販売する。ワクチン製品は予防的小児・青年・成人ワクチンを含み、医師の診療所において提供される。  メルクは米国の医薬品大手。医薬品、ワクチン、動物用医薬品、コンシュ―マ―ケア製品の発見、開発、製造、販売を行う。循環器・糖尿病、がん、骨・呼吸器、皮膚科・眼科、感染症、中枢神経、女性疾患の分野でブランドを展開。ペット用ワクチンや予防薬を提供。抗ヒスタミン剤「クラリトン」や便秘薬「ミララックス」などを扱う。  this site is intended only for residents of the united states and its territories. merck is known as msd outside the united states and canada. today's merck is a global healthcare leader working to help the world be well. through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. we also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. merck. be well. for more information, visit www.merck.com.
本社所在地 908 740-4000
代表者氏名 Kenneth C. Frazier
代表者役職名 Chairman of the Board President Chief Executive Officer
電話番号 +1 908-740-4000
設立年月日 10014
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 69000人
url www.merck.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 16729.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 214680.10000
売上高 売上高(百万ドル) 42294.00000
企業価値(EV) 企業価値(EV)(百万ドル) 230930.10000
当期純利益 当期純利益(百万ドル) 6220.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Merck_Co. Inc. revenues increased 5% to $42.29B. Net income before extraordinary items increased 25% to $6.22B. Revenues reflect Merck Pharmaceutical segment increase of 6% to $37.69B United States segment increase of 5% to $18.21B Europe Middle East and Africa segment increase of 6% to $12.21B. Net income benefited from IPR&D impairment charges decrease of 69% to $152M (expense).

 MRKのテクニカル分析


 MRKのニュース

   Merck sues to stop Biden''s drug-negotiation program  2023/06/08 11:32:15 InsuranceNewsNet
Drugmaker Merck& Co. filed a lawsuit Tuesday alleging President Biden''s marquee effort to negotiate down the cost of drugs under Medicare is "tantamount to extortion" and violates the Constitution. Merck wants the court to block the Biden administration from enforcing the program, saying at least one of its drugs will be selected for the program and expose the… The post Merck sues to stop Biden''s drug-negotiation program appeared first on Insurance News | InsuranceNewsNet .
   Merck marketing application for Keytruda in liver cancer granted FDA review  2023/06/08 11:07:34 Seeking Alpha
Merck (MRK) announced Thursday that the FDA accepted its marketing application seeking approval for Keytruda as a drug combo for a type of liver cancer. Read more here.
   FDA Accepts Application for Merck’s KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer  2023/06/08 10:45:00 Wallstreet:Online
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the treatment of patients with locally advanced
   FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer  2023/06/08 10:45:00 Business Wire
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
   Contraceptives Market to Witness Huge Growth by 2029 | Merck, Johnson & Johnson, Allergan  2023/06/08 10:33:20 OpenPR
The Latest Released Contraceptives market study has evaluated the future growth potential of Global Contraceptives market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help
   Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report  2023/05/01 17:29:00 Seeking Alpha
Abbvie (ABBV) and Bristol-Myers Squibb (BMY) competed to takeover Prometheus Biosciences (RXDX), before Merck (MRK) won in its pursuit of the biotech company. The interest from…
   AbbVie, Bristol Myers Vied for Prometheus Before Merck Bought It - BNN Bloomberg  2023/05/01 17:04:23 BNN Bloomberg
Merck & Co. edged out competitors including AbbVie Inc. and Bristol Myers Squibb Co. to prevail in its $10.8 billion takeover of biotechnology company Prometheus Biosciences Inc, according to people familiar with the matter.
   The Targeted Therapy Market Is Projected To Grow At An 8% Rate Through The Forecast Period As Per The Business Research Company''s Targeted Therapy Global Market Report 2023  2023/05/01 15:30:00 Benzinga
LONDON, May 01, 2023 (GLOBE NEWSWIRE) -- The Business Research Company''s research on the targeted therapy market forecasts that the market is expected to expand from $97.3 billion in 2022 to $106.7 billion in 2023 , at a compound annual growth rate (CAGR) of more than 9 % . The targeted therapy market share is then projected to grow to $148.3 billion in 2027 at a CAGR of more than 8%. North America was the largest region in the market in 2022. The growing incidence of cancer is expected to drive the expansion of the targeted therapy market size in the coming years. According to the American Cancer Society''s 2021 report, 1.8 million new cases of cancer were diagnosed in 2020. The National Cancer Institute, a US government organization that is part of the National Institutes of Health, reported a 43% increase in new cancer cases registered in September 2020 compared to 2019. Learn More In-Depth On The Targeted Therapy Industry https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report Several prominent players operating in the targeted therapy market include Sanofi, Merck & Co., Inc., Pfizer Inc., …
   The AUD is the strongest and the JPY is the weakest as the North American session begins  2023/05/01 12:08:23 Forexlive
The AUD is the strongest and the JPY is the weakest as new week, the new month and the North American session begins. The USD is mixed with the USD stronger vs the JPY, GBP, CAD, NZD and EUR and down vs the AUD and the CHF. Europe is mostly closed for May Day holiday. The AUDUSD moved above its 100 hour MA and swing lows from March 24 and April 10 were broken between 0.6618 and 0.6625, and that helped to push the pair higher. The next target goes between 0.6649 and 0.6852 (see green numbered circles in the chart below). Over the weekend, First Republic Bank has been taken over by Californian authorities, with JPMorgan Chase assuming its deposits, after more than $100 billion in deposits left the bank in Q1. It is the 3rd bank failure this year. This week, the big news will include the Fed meeting on Wednesday. The Federal Reserve is expected to increase interest rates by a quarter percentage point in its policy-setting meeting which some believer could be the last increase in its year-long tightening cycle.
   Bristol Myers, Merck anemia therapy undergoes U.S. and EU review for label expansion  2023/05/01 11:51:02 Seeking Alpha
The U.S. and EU regulators have agreed to review potential label expansion for anemia therapy Reblozyl developed by Bristol Myers (BMY) and Merck (MRK). Read more here.
   Pfizer reported weighing purchase of cancer drugmaker Seagen  2023/03/02 18:26:30 Big News Network
NEW YORK CITY, New York: The Wall Street Journal has reported that Pfizer is in early-stage discussions regarding a potential multi-billion dollar deal to acquire cancer drugmaker Seagen. The move comes after advanced discussions in 2022 between Merck and Seagen fell through, due to concerns that the Federal Trade Commission would launch an antitrust investigation of both companies. The report said the of
   Merck and AstraZeneca to face FDA AdCom meeting for prostate cancer therapy  2023/03/02 14:39:19 Seeking Alpha
Merck (MRK) and AstraZeneca (AZN) said Thursday that an FDA expert panel is set to discuss the company’s request to expand the label for cancer therapy Lynparza. Read the full story here.
   Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer  2023/03/02 14:00:00 Wallstreet:Online
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss the supplemental new drug application (sNDA) for use of LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of
   Sleep Apnea Devices Market: Technological Advancements and Innovations Driving Growth  2023/03/01 19:42:00 SBWire
ResMed (US), Koninklijke Philips N.V. (Netherlands) and Fisher & Paykel Healthcare (New Zealand) are leading players in Sleep Apnea Devices Market Northbrook, IL 60062 -- ( SBWIRE ) -- 03/01/2023 -- The sleep apnea devices industry is expected to continue to experience growth in the near future. This is due in part to an aging population, increasing awareness of sleep apnea, and advancements in technology. In the near future, we can expect to see more innovative solutions to treat sleep apnea, such as wearable devices and connected technologies. We can also expect to see an increased focus on patient-centered care and greater access to sleep apnea treatments. Additionally, the sleep apnea devices industry is likely to benefit from an increase in government funding and research grants, as well as greater acceptance of alternative treatments. Sleep Apnea Devices market in terms of revenue was estimated to be worth $7.1 billion in 2021 and is poised to reach $9.9 billion by 2026, growing at a CAGR of 6.9% from 2021 to 2026 according to a latest report published by MarketsandMarkets™.
   Merck says Keytruda trial met main goal as perioperative therapy in lung cancer  2023/03/01 12:26:06 Seeking Alpha
Merck (MRK) announced Wednesday its immunotherapy Keytruda reached one of the dual primary endpoints in a Phase 3 trial as perioperative therapy in lung cancer. Read the full story here.

 関連キーワード  (医薬品 米国株 MRK メルク MRK )

 twitter  (公式ツイッターやCEOツイッターなど)

MRK動画